Maxillo-facial & ENT Surgery, Istituto Nazionale Tumori IRCCS di Napoli "Fondazione G. Pascale", Napoli, Italy.
Head & Neck Oncology, Istituto Nazionale Tumori IRCCS di Napoli "Fondazione G. Pascale", Napoli, Italy.
Oral Oncol. 2019 May;92:77-84. doi: 10.1016/j.oraloncology.2019.03.016. Epub 2019 Mar 28.
To describe outcomes of Electrochemotherapy as palliative treatment in patients with advanced head and neck (H&N) tumours.
Ninety-three patients (120 treatment sessions) with H&N recurrent and/or metastatic neoplasm were treated. Treatment response was assessed 4 weeks after ECT with clinical examination and two months after the first evaluation with a CT scan of the H&N for deep lesions evaluation. The grade of bleeding and pain before, at the end of treatment and one week after ECT were evaluated.
Five percent of complete responses, 40% of partial responses were registered. Disease progression was seen in 20% of patients after the first ECT procedure, the remaining 34% of patients experienced stable disease. A good control of pain and bleeding was obtained, especially in patients with moderate symptoms before the treatment. No toxicities related to ECT were seen.
ECT is an interesting antitumoral therapy in advanced chemo and radio-refractory H&N neoplasms. ECT is able to reduce frequent symptoms, such as pain and bleeding, improving quality of life without damage to healthy tissue and with limited side effects. Moreover, ECT reduces hospitalization time and may contribute to an overall reduction in healthcare costs associated with advanced H&N cancers care.
描述电化学疗法(ECT)作为晚期头颈部(H&N)肿瘤姑息治疗的结果。
对 93 例(120 次治疗)H&N 复发性和/或转移性肿瘤患者进行治疗。ECT 治疗后 4 周通过临床检查和首次评估后两个月对 H&N 的 CT 扫描评估深部病变来评估治疗反应。在 ECT 之前、治疗结束时和 ECT 后一周评估出血和疼痛的程度。
登记了 5%的完全缓解和 40%的部分缓解。20%的患者在第一次 ECT 后出现疾病进展,其余 34%的患者疾病稳定。疼痛和出血得到了很好的控制,尤其是在治疗前有中度症状的患者。未观察到与 ECT 相关的毒性。
ECT 是一种针对晚期化疗和放疗耐药性 H&N 肿瘤的有趣的抗肿瘤治疗方法。ECT 能够减轻疼痛和出血等常见症状,改善生活质量,同时不会对健康组织造成损害,且副作用有限。此外,ECT 缩短了住院时间,并可能有助于降低与晚期 H&N 癌症治疗相关的总体医疗保健成本。